Bradley McGregor, MD

Articles

Dr. McGregor on Advances Made in the Adjuvant Setting of RCC

June 8th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Dr. McGregor on the Future of Cabozantinib in RCC

May 24th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the future of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).

Dr. McGregor on the Utility of Axitinib/Avelumab in Advanced RCC

May 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the data with the combination of axitinib (Inlyta) and avelumab (Bavencio) in advanced renal cell carcinoma (RCC).

Dr. McGregor on Frontline Regimens in Advanced RCC

May 10th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses frontline treatment regimens in advanced renal cell carcinoma (RCC).

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC

May 4th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers

October 2nd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

September 11th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Dr. McGregor Compares Recent Data With Combinations in RCC

June 6th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma.

Dr. McGregor on New Combinations With Immunotherapy in RCC

May 23rd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Dr. McGregor on Immunotherapy Combinations in Kidney Cancer

April 7th 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Dr. McGregor Discusses the Future of Treatment for RCC

September 19th 2017

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.